OPKO Health Appoints Dr. Benjamin Solomon as Managing Director of GeneDx

September 27, 2016 8:30am EDT

Download as PDF

MIAMI--(BUSINESS WIRE)--

OPKO Health, Inc. (NASDAQ:OPK) , announces the appointment of

Benjamin D. Solomon, M.D. as Managing Director of GeneDx, effective as

of October 3, 2016. GeneDx, part of OPKO’s BioReference Laboratories

subsidiary, specializes in genetic testing for rare hereditary disorders.

Dr. Solomon is a pediatric geneticist who focuses on the use of genetics

and genomics to identify, understand and care for patients with both

rare and common genetic conditions. He is a leader in integrating

cutting-edge technologies to better manage health and disease. He most

recently served as Chief of the Division of Medical Genomics at the

Inova Translational Medicine Institute, a clinical research institute

dedicated to putting genomic medicine into action.

“We are very proud to have Dr. Solomon join the OPKO Health team as the

new leader of our GeneDx division, a world-class genomics laboratory. A

recognized leader in his field, Dr. Solomon’s expertise in genomics and

genetics will be of great value as we continue to leverage leading

technologies to build and expand GeneDx’s global role in diagnostic and

laboratory services. His passion for finding answers for patients and

clinicians and his talent and experience in the integration of genomics

into the practice of medicine will enhance the numerous and diverse

communities in the U.S. and worldwide that benefit from the outstanding

diagnostic services our laboratories offer,” said Gregory S. Henderson,

M.D., Ph.D., President of BioReference Laboratories.

In addition to his clinical and research leadership and advocacy, Dr.

Solomon has published more than 100 peer-reviewed articles and book

chapters, is co-editor of the most recent edition of the textbook Human

Malformations , and is an active lecturer and educator. Dr. Solomon

attended medical school at the Geisel School of Medicine at Dartmouth

College and completed his residency and fellowship training in pediatric

medicine and clinical genetics at the National Human Genome Research

Institute at the National Institutes of Health and at Children’s

National Medical Center. He is board-certified in clinical genetics and

pediatrics.

About OPKO Health, Inc.

OPKO Health, Inc. is a diversified healthcare company that seeks to

establish industry-leading positions in large, rapidly growing markets.

Our diagnostics business includes BioReference Laboratories, the

nation's third-largest clinical laboratory with a core genetic testing

business and a 420-person sales force to drive growth and leverage new

products, including the 4Kscore® prostate cancer test and the Claros®

1 in-office immunoassay platform. Our pharmaceutical business

features RAYALDEE® , an FDA-approved treatment for SHPT in stage

3-4 CKD patients with vitamin D insufficiency, and VARUBI™ for

chemotherapy-induced nausea and vomiting (oral formulation launched by

partner Tesaro and IV formulation PDUFA is January 2017). Our biologics

business includes hGH-CTP, a once-weekly human growth hormone injection

(in Phase 3 and partnered with Pfizer), a long-acting Factor VIIa drug

for hemophilia (in Phase 2a) and a long-acting oxyntomodulin for

diabetes and obesity (in Phase 1). We also have production and

distribution assets worldwide, multiple strategic investments and an

active business development strategy. More information is available at www.opko.com .

Cautionary Statement Regarding Forward-Looking Statements

This press release contains "forward-looking statements," as that

term is defined under the Private Securities Litigation Reform Act of

1995 (PSLRA), which statements may be identified by words such as

"expects," "plans," "projects," "will," "may," "anticipates,"

"believes," "should," "intends," "estimates," and other words of similar

meaning, including statements regarding synergies, benefits and

opportunities of the transaction, future opportunities for the combined

company and products, the potential for Transition Therapeutics’

products and whether they will benefit patients suffering with metabolic

and androgen deficiency diseases, the growth, development and strength

of OPKO’s pipeline, as well as other non-historical statements about our

expectations, beliefs or intentions regarding our business, technologies

and products, financial condition, strategies or prospects. Many factors

could cause our actual activities or results to differ materially from

the activities and results anticipated in forward-looking statements.

These factors include those described in our Annual Reports on Form 10-K

filed and to be filed with the Securities and Exchange Commission and in

our other filings with the Securities and Exchange Commission. The

forward-looking statements contained in this press release speak only as

of the date the statements were made, and we do not undertake any

obligation to update forward-looking statements. We intend that all

forward-looking statements be subject to the safe-harbor provisions of

the PSLRA.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160927005597/en/

OPKO Health, Inc.

Company

Tara Mackay, 305-575-4100

Investor

Relations

or

Media

RooneyPartners

Terry

Rooney, 212-223-0689

or

Marion

Janic, 212-223-4017

or

Investors

LHA

Anne

Marie Fields, 212-838-3777

or

Bruce

Voss, 310-691-7100

Source: OPKO Health, Inc.

Released September 27, 2016

email Email Alerts

location_city Company Profile

contact_page Contacts

rss_feed RSS News Feed

account_tree Sitemap